Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04194229
Other study ID # PR-C
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 11, 2016
Est. completion date January 2021

Study information

Verified date December 2021
Source POLYSAN Scientific & Technological Pharmaceutical Company
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objective - to assess the effect of Cytoflavin® and its tolerability within the integrated program of rehabilitation of patients who underwent ischemic stroke


Description:

Cerebral stroke (CS) remains one of the key issues of modern society, being a predominant cause of deep and persistent disability of the population. Huge social and economic damage arising from cerebrovascular diseases raises the problem of improving medical care for strokes among the most relevant scientific and practical tasks of neurology Regulation of energy metabolism is considered a powerful tool for acute conditions relief, including those that occur due to acute impairment of cerebral blood flow. A number of adjuvant energy protector concomitant medications with systemic pharmacodynamic properties based on signaling (hormonal) and substrate mode of action of succinic acid and other mitochondrial substrates and co-factors was created for this A significant role in the rehabilitation of patients who underwent CS is assigned to the treatment of complications of care in the intensive care unit, the so-called post-intensive care syndrome (PICS), which is a set of somatic, neurological, social and psychological consequences of periods in intensive care unit (ICU) conditions that bring limitations to the patient's daily activities In the Brain Institute Clinic (Ekaterinburg), the first results of the metabolic status monitoring during physical and cognitive exercise in patients with PICS were obtained. These results prove that control over metabolic state holds the promise of developing approaches to increasing exercise tolerance Taking into account the effectiveness of Cytoflavin® in treatment of acute impairment of cerebral circulation and consequences of cerebrovascular diseases, on the one hand, and its classification as a metabotropic energy corrector, on the other hand, the evaluation of Cytoflavin® medication tolerability in the integrated program of neurorehabilitation of patients with PICS after ischemic stroke presents a significant interest.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 2021
Est. primary completion date January 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women aged 18 years and above; - Patients who underwent ischemic stroke; - The period from the development of ischemic stroke is not less than 12 and not more than 28 days; - Staying in intensive care unit for no less than 72 hours; - Diagnosed post-intensive care syndrome (PICS); - Functional status assessed using the modified Rankin scale amounts to 4-5; - Gravity gradient of 20° to 40° upon inclusion in observational non-interventional program Exclusion Criteria: - Vegetative state; - Mechanical ventilation lasting more than 72 hours after the development of ischemic stroke; - Surgical treatment for cerebral stroke (decompressive craniectomy; thromboextraction etc.); - Premorbid (before the development of ischemic stroke) level of functional activity assessed using the modified Rankin scale amounts to 4 or 5; - Signs of increasing neurological deficit or enlargement of hypoperfusion zones on CT scans within 24 hours before inclusion in observational non-interventional program; - Level of consciousness = 5 according to Glasgow Coma Scale and/or = 1 according to Richmond Agitation-Sedation Scale (RASS); - Behavioral Pain Scale (BPS) or Visual Analogue Scale assessment score of more than > 0 at the moment of inclusion; - Systolic blood pressure < 90 and > 180 mm Hg; - Diastolic blood pressure = 110 mm Hg; - Mean ABP < 60 mm Hg; - Clinical and/or electrocardiographic signs of acute coronary syndrome (including de novo ST elevation or depression, negative T-waves amplitude formation and buildup, formation of pathological Q-wave, increase in the level of markers of myocardial injury - troponin T or I, creatine phosphokinase-MB, LDH-1), or diagnosed acute myocardial infarction occurring within a month before inclusion in observational program; - Acute heart arrhythmias; - Heart rate (HR) < 60 or > 100 per minute; - Spontaneous respiration rate (RR) < 10 or > 30 per minute; - Arterial oxygen saturation (SpO2) < 90 %; - Venous serum glucose level = 4 mmol/L; - Axillary body temperature = 38.5 °C; - Hematocrit = 30 %; - Level of hemoglobin = 80 g/l; - Serum total protein = 55 g/l; - Positive passive leg raising test (PRL-test); - Acute heart failure; - Acute respiratory failure; - Acute kidney injury; - Acute liver cell failure; - Congestive heart failure; - Chronic respiratory failure, stage greater than I; - Chronic kidney disease with estimated glomerular filtration rate using Cockcroft-Gault formula < 60 ml/min/1.73 m2; - Clinically significant deviations in the results of complete blood count, blood chemistry, common urine analysis, except those that are acceptable according to other non inclusion criteria; - Purulent-inflammatory diseases at any location; - Refuse of the patient to undergo verticalization or exercise sessions; - Use of medicinal products belonging to the pharmaceutical therapeutic category of metabolic drugs at the time of inclusion in observational non-interventional program, as well as plans for their use during study; - Plans for use of physical rehabilitation methods other than verticalization and cycling exercise sessions during the course of the program.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Russian Federation Brain Institute Clinic Ekaterinburg Sverdlovsk Region

Sponsors (1)

Lead Sponsor Collaborator
POLYSAN Scientific & Technological Pharmaceutical Company

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Median time to achieving gravity gradient of 90° Median time (in days) to achieving gravity gradient of 90°. 10 days
Secondary Proportion of patients who achieved gravity gradient of 90° Proportion of patients who achieved gravity gradient of 90° by day 5 and 10 days of rehabilitation activities 5 and 10 days
Secondary Change in of oxygen consumption during 90° verticalization Change in of oxygen consumption during 90° verticalization 5 and 10 days
Secondary Change in the Medical Research Council (MRC) scale for muscle strength score Medical Research Council scale for muscle power (MRC), where 0 - tetraplegia, 60 - normal value 5 and 10 days
Secondary Change in Barthel index (BI) Barthel index (BI), when 0 - complete inability to self-service, 100 - full capability of self-service 5 and 10 days of rehabilitation activities
Secondary Change in Modified Rankin scale (MRS) score Modified Rankin scale (MRS), when 0 - no disability, 5 - severe disability 5 and 10 days of rehabilitation activities
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2